A Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic of SNH-119014 in Healthy Adult Volunteers
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
SNH-119014 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of SNH-119014 in the context of Phase 1 studies in healthy volunteers. The effects of food on the absorption of SNH-119014 will also be evaluated in healthy volunteers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: t
View:
• Healthy male or female subjects;
• 18-45 years of age, inclusive;
• Male subjects with body weight ≥50 kg, female subjects with body weight ≥45 kg; BMI ≥18.5 and ≤28.0 kg/m2.
• Must provide written informed consent.
Locations
Other Locations
China
The Second Hospital of Anhui Medical University
RECRUITING
Hefei
Contact Information
Primary
Wei Hu, Ph.D
huwei@ahmu.edu.com
86010-3856086475
Time Frame
Start Date: 2025-06-27
Estimated Completion Date: 2026-03-28
Participants
Target number of participants: 96
Treatments
Experimental: SNH-119014
Placebo_comparator: placebo
Related Therapeutic Areas
Sponsors
Leads: ScinnoHub Pharmaceutical Co., Ltd.